All News

VenoStent wins Prestigious $500,000 KidneyX, Redefining Dialysis Prize

Jul, 22, 2020

We are so pleased to be recognized as a KidneyX winner of both $500,000 in prize money and, equally as valuable, the collaboration with the American Society of Nephrology and the Department of Health and Human Services.

Kidney disease impacts 850 million people worldwide, 37 million in the United States. There are only two treatment options for people who progress to kidney failure, a rare kidney transplant or dialysis. While dialysis is a lifesaving treatment for 500,000 Americans, it has changed very little in more than fifty years. Until now.

KidneyX, a public-private partnership between the US Department of Health and Human Services and the American Society of Nephrology, is accelerating innovation in the treatment of kidney diseases through prize competitions. To date, KidneyX has distributed more than $4,000,000 in prizes propelling positive incremental and transformative change to kidney replacement therapy.

The KidneyX Redesign Dialysis Phase 2 prize competition challenged participants to build and test prototype solutions, or components of solutions, that can replicate normal kidney functions or improve dialysis access.

Our innovation is helping to transform a stagnant field lacking transformative innovation. Thanks to the roadmap, partnership, and networks that ASN and HHS have laid out in KidneyX, we are turning vision into action to transform the future of kidney care.

SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational Device. Limited by Federal Law to Investigational Use.

© Copyright 2021 VenoStent, Inc.
Contact Usinfo@venostent.com
2450 Holcombe Blvd, Suite J Houston, TX 77021
Follow Us